Mechanisms of Autism Spectrum Disorder and Pharmacological Approach

doi:10.3969/j.issn.2095-1396.2016.06. 006

Abstract

Abstract: Autism spectrum disorder （ASD） is a heterogeneous group of bio-neurological developmental disorders that displays common behavioral symptoms， including pervasive impairments in social interactions， accompanied by communication challenges and repetitive behaviors. Present review highlighted the advances on molecular mechanisms of autism， also summary the present pharmacological interventions for abnormal symptoms during ASD clinical therapy.

Key words: autism spectrum disorder（ ASD）, molecular mechanism, drug therapy

LONG Sen，CHEN Jia-ye，HAN Feng. Mechanisms of Autism Spectrum Disorder and Pharmacological Approach[J]. Acta Neuropharmacologica, 2016, 6(6): 55-64.

References

[1] Deborah L Christensen, Jon Baio, Kim Van Naarden Braun, et al.Prevalence of autism spectrum disorder among children aged 8 years-autism and developmental disabilities monitoring network, 11 sites, United States, 2010[J]. MMWR Surveill Summ, 2014, 63(2): 1-21.

[2] Young Shin Kim, Bennett L Leventhal, Yun-Joo Koh, et al. Prevalence of autism spectrum disorders in a total population sample[J]. Am J Psychiatry, 2011, 168(9): 904-912.

[3] Jeffrey J Hutsler, Zhang Hong. Increased dendritic spine densities on cortical projection neurons in autism spectrum disorders[J]. Brain Res, 2010, 1309: 83-94.

[4] Deborah K Sokol, Mary Edwards-Brown. Neuroimaging in autistic spectrum disorder (ASD)[J]. J Neuroimaging, 2004, 14(1):8-15.

[5] Natalia M Kleinhans, Todd Richards, L Clark Johnson, et al. fMRI evidence of neural abnormalities in the subcortical face processing system in ASD[J]. Neuroimage, 2011, 54(1): 697-704.

[6] Geir Bjorklund. The role of zinc and copper in autism spectrum disorders[J]. Acta Neurobiol Exp (Wars), 2013, 73(2): 225-236.

[7] Ghanizadeh A. Gold implants and increased expression of metallothionein-I/II as a novel hypothesized therapeutic approach for autism[J]. Toxicology, 2011, 283(1):63-64.

[8] Jakob Christensen, Therese Koops Gronborg, Merete Juul Sorensen, et al. Prenatal valproate exposure and risk of autism spectrum disorders and childhood autism[J]. JAMA, 2013, 309(16): 1696-1703.

[9] Patricia A Stewart, Susan L Hyman, Brianne L Schmidt, et al. Dietary supplementation in children with autism spectrum disorders: common, insufficient, and excessive[J]. J Acad Nutr Diet, 2015, 115(8):1237-1248.

[10] 王安莲, 刘志荣. 自闭症研究现状[J]. 安徽预防医学杂志, 2013(05):367-371.

[11] 曹涛, 余丹, 黄伏生. 遗传因素和环境因素在自闭症中的作用[J]. 中华临床医师杂志:电子版, 2015(21):3952-3957.

[12] 曹漱芹, 方俊明. 自闭症谱系障碍语义加工特点与认知神经机制的研究综述[J]. 中国特殊教育, 2008(09):27-34.

[13] Emma J Grinter, Murray T Maybery, Elizabeth Pellicano, et al. Perception of shapes targeting local and global processes in autism spectrum disorders [J]. J Child Psychol Psychiatry, 2010, 51(6): 717-724..

[14] 王丽娟, 罗红格, 姚雪. 自闭症谱系障碍者面孔识别的神经机制[J]. 心理科学进展, 2009, (06):1177-1184.

[15] 仇子龙. 解开自闭症谜团的钥匙—突触[J]. 生命的化学, 2013, (06):716-719.

[16] Tang Guo-mei, Kathryn Gudsnuk, Kuo Sheng-han, et al. Loss of mTOR-dependent macroautophagy causes autistic-like synaptic pruning deficits[J]. Neuron, 2014, 83(5):1131-1143.

[17] Catherine Hanson, Stephen Jose Hanson, Joseph Ramsey, et al. Atypical effective connectivity of social brain networks in individuals with autism[J]. Brain Connect, 2013, 3(6):578-589.

[18] Franco Cauda, Elisabetta Geda, Katiuscia Sacco, et al. Grey matter abnormality in autism spectrum disorder: an activation likelihood estimation meta-analysis study[J]. J Neurol Neurosurg Psychiatry, 2011, 82(12):1304-1313.

[19] Richetto J, Chesters R, Cattaneo A, et al. Genome-wide transcriptional profiling and structural magnetic resonance imaging in the maternal immune activation model of neurodevelopmental disorders[J]. Cereb Cortex, 2017, 27(6):3397-3413.

[20] Federica Piras, Fabrizio Piras, Carlo Caltagirone, et al. Brain circuitries of obsessive compulsive disorder: a systematic review and meta-analysis of diffusion tensor imaging studies[J]. Neurosci Biobehav Rev, 2013, 37(10 Pt 2): 2856-2877.

[21] Jane McGrath, Katherine Johnson, Erik O'Hanlon, et al. Abnormal functional connectivity during visuospatial processing is associated with disrupted organisation of white matter in autism[J]. Front Hum Neurosci, 2013, 7: 434.

[22] 邵世怡, 陈琳, 蒋权, 等. 基于突触功能异常的自闭症发病机制研究进展[J]. 中国现代应用药学, 2016, (04):501-508.

[23] Patricia Monteiro, Feng Guo-ping. SHANK proteins: roles at the synapse and in autism spectrum disorder[J]. Nat Rev Neurosci, 2017, 18(3):147-157.

[24] A Ozge Sungur, Magdalena Jochner, Hani Harb, et al. Aberrant cognitive phenotypes and altered hippocampal BDNF expression related to epigenetic modifications in mice lacking the post-synaptic scaffolding protein SHANK1: Implications for autism spectrum disorder[J]. Hippocampus, 2017, 27(8): 906-919.

[25] Daisuke Sato, Anath C Lionel, Claire S Leblond, et al. SHANK1 deletions in males with autism spectrum disorder[J]. Am J Hum Genet, 2012, 90(5):879-887.

[26] Simone Berkel, Christian R Marshall, Birgit Weiss, et al. Mutations in the SHANK2 synaptic scaffolding gene in autism spectrum disorder and mental retardation[J]. Nat Genet, 2010, 42(6):489-491.

[27] Julie Gauthier, Dan Spiegelman, Amelie Piton, et al. Novel de novo SHANK3 mutation in autistic patients[J]. Am J Med Genet B Neuropsychiatr Genet, 2009, 150B(3):421-424.

[28] Rainald Moessner, Christian R Marshall, James S Sutcliffe, et al. Contribution of SHANK3 mutations to autism spectrum disorder[J]. Am J Hum Genet, 2007, 81(6):1289-1297.

[29] Andrea K Vaags, Anath C Lionel, Daisuke Sato, et al. Rare deletions at the neurexin 3 locus in autism spectrum disorder[J]. Am J Hum Genet, 2012, 90(1):133-141.

[30] Julie Gauthier, Tabrez J Siddiqui, Peng Hua-shan, et al. Truncating mutations in NRXN2 and NRXN1 in autism spectrum disorders and schizophrenia[J]. Hum Genet, 2011, 130(4):563-573.

[31] Mukherjee K, Sharma M, Urlaub H, et al. CASK Functions as a Mg2+-independent neurexin kinase[J]. Cell, 2008, 133(2):328-339.

[32] Hu Zhi-tao, Sabrina Hom, Tambudzai Kudze, et al. Neurexin and neuroligin mediate retrograde synaptic inhibition in C. elegans[J]. Science, 2012, 337(6097):980-984.

[33] Liu Ya-lan, Hu Zheng-mao, Xun Guang-lei, et al. Mutation analysis of the NRXN1 gene in a Chinese autism cohort[J]. J Psychiatr Res, 2012, 46(5): 630-634.

[34] Jessica A Burket, Andrew D Benson, Amy H Tang, et al. D-Cycloserine improves sociability in the BTBR T+ Itpr3tf/J mouse model of autism spectrum disorders with altered Ras/Raf/ERK1/2 signaling[J]. Brain Res Bull, 2013, 96: 62-70.

[35] Yang Xue-feng, Mei Shuang, Wang Xiao-lei, et al. Leucine facilitates insulin signaling through a Galphai protein-dependent signaling pathway in hepatocytes[J]. J Biol Chem, 2013, 288(13):9313-9320.

[36] Schauwienold D, Plum C, Helbing T, et al. ERK1/2-dependent contractile protein expression in vascular smooth muscle cells[J]. Hypertension, 2003, 41(3):546-552.

[37] Yang K, Sheikh A M, Malik M, et al. Upregulation of Ras/Raf/ERK1/2 signaling and ERK5 in the brain of autistic subjects[J]. Genes Brain Behav, 2011, 10(8):834-843.

[38] Tian Yun, Yasushi Yabuki, Shigeki Moriguchi, et al. Melatonin reverses the decreases in hippocampal protein serine/threonine kinases observed in an animal model of autism[J]. J Pineal Res, 2014, 56(1):1-11.

[39] Joaquin N Lugo, Gregory D Smith, Erin P Arbuckle, et al. Deletion of PTEN produces autism-like behavioral deficits and alterations in synaptic proteins[J]. Front Mol Neurosci, 2014, 7: 27.

[40] Chang-Hyuk Kwon, Bryan W Luikart, Craig M Powell, et al. Pten regulates neuronal arborization and social interaction in mice[J]. Neuron, 2006, 50(3):377-388.

[41] Hendrik Wesseling, Ype Elgersma, Sabine Bahn. A brain proteomic investigation of rapamycin effects in the Tsc1+/- mouse model[J]. Mol Autism, 2017, 8: 41.

[42] Atsushi Sato, Shinya Kasai, Toshiyuki Kobayashi, et al. Rapamycin reverses impaired social interaction in mouse models of tuberous sclerosis complex[J]. Nat Commun, 2012, 3: 1292.

[43] Gaia Kulman, Paolo Lissoni, Franco Rovelli, et al. Evidence of pineal endocrine hypofunction in autistic children[J]. Neuro Endocrinol Lett, 2000, 21(1):31-34.

[44] Hariom Kumar, B M Sharma, Bhupesh Sharma. Benefits of agomelatine in behavioral, neurochemical and blood brain barrier alterations in prenatal valproic acid induced autism spectrum disorder[J]. Neurochem Int, 2015,91:34-45.

[45] Beth Malow, Karen W Adkins, Susan G McGrew, et al. Melatonin for sleep in children with autism: a controlled trial examining dose, tolerability, and outcomes[J]. J Autism Dev Disord, 2012, 42(8):1729-1737, 1738.

[46] Hong Ling-juan, Jiang Quan, Long Sen, et al. Valproic acid influences MTNR1A intracellular trafficking and signaling in a beta-arrestin 2-dependent manner[J]. Mol Neurobiol, 2016, 53(2):1237-1246.

[47] Xu Ningan, Li Xiao-hong, Zhong Yan. Inflammatory cytokines: potential biomarkers of immunologic dysfunction in autism spectrum disorders[J]. Mediators Inflamm, 2015, 2015:531518.

[48] Arti B Patel, Irene Tsilioni, Susan E Leeman, et al. Neurotensin stimulates sortilin and mTOR in human microglia inhibitable by methoxyluteolin, a potential therapeutic target for autism[J]. Proc Natl Acad Sci USA, 2016, 113(45):E7138.

[49] Mushtaq A Ansari, Ahmed Nadeem, Sabry M Attia, et al. Adenosine A2A receptor modulates neuroimmune function through Th17/retinoid-related orphan receptor gamma t (RORgammat) signaling in a BTBR T+ Itpr3tf/J mouse model of autism[J]. Cell Signal, 2017, 36: 14-24.

[50] Johnny L Matson, Marie Nebel-Schwalm. Assessing challenging behaviors in children with autism spectrum disorders: a review[J]. Res Dev Disabil, 2007, 28(6):567-579.

[51] Luc Lecavalier. Behavioral and emotional problems in young people with pervasive developmental disorders: relative prevalence, effects of subject characteristics, and empirical classification[J]. J Autism Dev Disord, 2006, 36(8):1101-1114.

[52] L Eugene Arnold, Cristan Farmer, Helena Chmura Kraemer, et al. Moderators, mediators, and other predictors of risperidone response in children with autistic disorder and irritability[J]. J Child Adolesc Psychopharmacol, 2010, 20(2):83-93.

[53] 谢琴, 黄卓玮, 王朔, 等. 利培酮口服液治疗儿童孤独症32例的疗效及安全性[J]. 中国新药杂志, 2013, (08):941-944.

[54] 郭海燕, 周雨林, 刘淑华. 利培酮口服液治疗儿童孤独症疗效分析[J]. 中国医药指南, 2012, (03):142-143.

[55] Adelaide Robb, Candace Andersson, Elizabeth E Bellocchio, et al. Safety and tolerability of aripiprazole in the treatment of irritability associated with autistic disorder in pediatric subjects (6-17 years old):results from a pooled analysis of 2 studies[J]. Prim Care Companion CNS Disord, 2011, 13(1).

[56] Ahmad Ghanizadeh, Aliakbar Sahraeizadeh, Michael Berk. A head-to-head comparison of aripiprazole and risperidone for safety and treating autistic disorders, a randomized double blind clinical trial[J]. Child Psychiatry Hum Dev, 2014, 45(2):185-192.

[57] 孙凌, 周天红, 张嫦, 等. 帕利哌酮缓释片治疗孤独症的开放性研究[J]. 中国新药杂志, 2013, (09):1060-1063.

[58] 周天红, 孙凌, 崔炳喜, 等. 帕利哌酮缓释片与利培酮治疗孤独症的对照研究[J]. 天津医科大学学报, 2013, (05):399-402.

[59] Valiquette G. Risperidone in children with autism and serious behavioral problems[J]. N Engl J Med, 2002, 347(23):1890-1891.

[60] Joseph R Calabrese, Raymond Sanchez, Jin Na, et al. Efficacy and safety of aripiprazole once-monthly in the maintenance treatment of bipolar I disorder: a double-blind, placebo-controlled, 52-week randomized withdrawal study[J]. J Clin Psychiatry, 2017, 78(3):324-331.

[61] Hellings J A, Kelley L A, William Gabrielli, et al. Sertraline response in adults with mental retardation and autistic disorder[J]. J Clin Psychiatry, 1996, 57(8):333-336.

[62] Kolevzon A, Mathewson K A, Hollander E. Selective serotonin reuptake inhibitors in autism: a review of efficacy and tolerability[J]. J Clin Psychiatry, 2006, 67(3):407-414.

[63] Kenneth K C Man, Henry H Y Tong, Lisa Y L Wong, et al. Exposure to selective serotonin reuptake inhibitors during pregnancy and risk of autism spectrum disorder in children: a systematic review and meta-analysis of observational studies[J]. Neurosci Biobehav Rev, 2015, 49: 82-89.

[64] Liu Xian-chen, Julie A Hubbard, Richard A Fabes, et al. Sleep disturbances and correlates of children with autism spectrum disorders[J]. Child Psychiatry Hum Dev, 2006, 37(2):179-191.

[65] Polimeni M A, Richdale A L, Francis A J P. A survey of sleep problems in autism, Asperger's disorder and typically developing children[J]. J Intellect Disabil Res, 2005, 49(Pt 4):260-268.

[66] Kimberly A Schreck, James A Mulick, Angela F Smith. Sleep problems as possible predictors of intensified symptoms of autism[J]. Res Dev Disabil, 2004, 25(1):57-66.

[67] Mark T Harvey, Craig H Kennedy. Polysomnographic phenotypes in developmental disabilities[J]. Int J Dev Neurosci, 2002, 20(3-5):443-448.

[68] Egemen Savaskan, Anna Wirz-Justice, Gianfranco Olivieri, et al. Distribution of melatonin MT1 receptor immunoreactivity in human retina[J]. J Histochem Cytochem, 2002, 50(4):519-526.

[69] Egemen Savaskan, Mohammed A Ayoub, Rivka Ravid, et al. Reduced hippocampal MT2 melatonin receptor expression in Alzheimer's disease[J]. J Pineal Res, 2005, 38(1):10-16.

[70] Flavia Giannotti, Flavia Cortesi, A Cerquiglini, et al. An open-label study of controlled-release melatonin in treatment of sleep disorders in children with autism[J]. J Autism Dev Disord, 2006, 36(6):741-752.

[71] Flavia Cortesi, Flavia Giannotti, Teresa Sebastiani, et al. Controlled-release melatonin, singly and combined with cognitive behavioural therapy, for persistent insomnia in children with autism spectrum disorders: a randomized placebo-controlled trial[J]. J Sleep Res, 2012, 21(6):700-709.

[72] Doyen C, Mighiu D, Kaye K, et al. Melatonin in children with autistic spectrum disorders: recent and practical data[J]. Eur Child Adolesc Psychiatry, 2011, 20(5):231-239.

[73] Rossignol D A, Frye R E. Melatonin in autism spectrum disorders[J]. Curr Clin Pharmacol, 2014, 9(4):326-334.

[74] Sylvie Tordjman, Imen Najjar, Eric Bellissant, et al. Advances in the research of melatonin in autism spectrum disorders: literature review and new perspectives[J]. Int J Mol Sci, 2013, 14(10):20508-20542.

[75] 吕志强, 杨建云, 肖炳坤, 等. 褪黑素能类药物研究进展[J]. 国际药学研究杂志, 2013, (02):162-166.

[76] Kimberly A Stigler, David J Posey, Christopher J McDougle. Ramelteon for insomnia in two youths with autistic disorder[J]. J Child Adolesc Psychopharmacol, 2006, 16(5):631-636.

[77] Paola Giovanardi Rossi, Annio Posar, Antonia Parmeggiani, et al. Niaprazine in the treatment of autistic disorder[J]. J Child Neurol, 1999,14(8):547-550.

[78] Ming Xue, Emily Gordon, Kang Ning, et al. Use of clonidine in children with autism spectrum disorders[J]. Brain Dev, 2008, 30(7):454-460.

[79] 吴晖, 吴忠义. “三位一体”中医疗法治疗孤独症[J]. 医药产业资讯, 2006, (11):116-117.

[80] 严愉芬, 雷法清. 加味温胆汤配合教学训练矫治孤独症儿童异常行为25例[J]. 中医杂志, 2007, (03):244.

[81] 李永. 柴胡加桂枝龙骨牡蛎汤主方治疗自闭症21例[J]. 中国中医药现代远程教育, 2011, (22):57-58.

[82] 叶剑飞, 于海波, 阮俊, 等. 抗闭1号治疗小儿自闭症30例临床分析[J]. 中医临床研究, 2012, (07):38-39.

[83] Rachel M Zamzow, Bradley J Ferguson, Janine P Stichter, et al. Effects of propranolol on conversational reciprocity in autism spectrum disorder: a pilot, double-blind, single-dose psychopharmacological challenge study[J]. Psychopharmacology (Berl), 2016, 233(7):1171-1178.

[84] Rachel M Zamzow, Shawn Christ, Sanjida S Saklayen, et al. Effect of propranolol on facial scanning in autism spectrum disorder: a preliminary investigation[J]. J Clin Exp Neuropsychol, 2014, 36(4):431-445.

[85] Eric Lemonnier, Yehezkel Ben-Ari. The diuretic bumetanide decreases autistic behaviour in five infants treated during 3 months with no side effects[J]. Acta Paediatr, 2010, 99(12):1885-1888.

[86] Lemonnier E, Degrez C, Phelep M, et al. A randomised controlled trial of bumetanide in the treatment of autism in children[J]. Transl Psychiatry, 2012, 2:e202.